Synthetic antimicrobial related to OXOLINIC ACID and NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.
Dioxolanes are a class of cyclic ethers with a six-membered ring containing two oxygen atoms, used in various medical applications such as as antiseptics and anesthetics.
Pyridazines are a class of heterocyclic compounds with a six-membered ring containing five carbon atoms and one nitrogen atom, used in the medical field as drugs for various indications such as antipsychotics, antiemetics, and antihistamines.
A synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA GYRASE.
Substances capable of killing agents causing urinary tract infections or of preventing them from spreading.
Synthetic antimicrobial related to NALIDIXIC ACID and used in URINARY TRACT INFECTIONS.
Dioxoles are a class of heterocyclic compounds containing an oxygen atom and two carbon atoms in a six-membered ring.
A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.

Anaphylactic reactions to cinoxacin. (1/7)

During 1981 to mid-1988 three cases of anaphylactic shock after treatment with the quinolone derivative cinoxacin were reviewed by the Netherlands Centre for Monitoring of Adverse Reactions to Drugs and 17 cases of an anaphylactic type of reaction notified to the World Health Organisation Collaborating Centre for International Drug Monitoring. In five out of six patients for whom data were available the reaction began shortly after taking a single capsule of a second or next course of treatment. Cinoxacin is related to nalidixic acid, and one patient previously treated with that agent subsequently had an anaphylactoid reaction to cinoxacin and later developed a skin reaction to nalidixic acid. There were no deaths, and patients treated as an emergency with plasma expanders or with adrenaline and corticosteroids generally recovered promptly and uneventfully. In view of the potentially fatal consequences of anaphylactic reactions to cinoxacin and other quinolones doctors should take care when prescribing these drugs.  (+info)

Cinoxacin: effectiveness against experimental pyelonephritis in rats. (2/7)

The antimicrobial activity of cinoxacin, 1-ethyl-4(1H)-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid, previously reported as compound 64716, was determined and compared with other antimicrobial agents at a dosage of 12 mg/kg once daily in a descending pyelonephritis rat model with Escherichia coli and Proteus mirabilis as infecting organisms. Cinoxacin was considerably more effective than either nalidixic acid or oxolinic acid when all three were administered orally at 3 mg/kg four times daily. The presence of demonstrable serum activity with a high recovery in urine indicates cinoxacin possesses highly desirable properties of an effective oral chemotherapeutic agent for urinary tract infections.  (+info)

Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function. (3/7)

The pharmacokinetics of cinoxacin, a new antibacterial compound related to nalidixic acid and oxolinic acid, were investigated in 22 patients with varying degrees of renal impairment. After oral administration of cinoxacin at 500 mg every 12 h for 7 days to all patients, the drug was found to be well tolerated. The urine concentrations of cinoxacin in all patients far exceeded the minimal inhibitory concentrations for susceptible organisms commonly found in urinary tract infections. The serum half-life of cinoxacin in patients with normal renal function was approximately 2.7 h but increased to approximately 8.5 h in patients with creatinine clearance less than 30 ml/min. No undue drug accumulation was demonstrated in any patient group during the treatment. Highly significant correlations were found between the elimination rate constant and creatinine clearance and also between the elimination half-life and serum creatinine. The bioavailability of cinoxacin was independent of renal function.  (+info)

In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis. (4/7)

The in vitro activities of five quinolinecarboxylic acids against two laboratory strains of Chlamydia trachomatis were compared. The minimal inhibitory concentrations of nalidixic acid, cinoxacin, and pipemidic acid were all greater than or equal to 50 micrograms/ml; the activity of norfloxacin was intermediate (minimal inhibitory concentration, 8 to 16 micrograms/ml). Ciprofloxacin was the most active of these drugs (minimal inhibitory concentration, 0.5 to 1 microgram/ml).  (+info)

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. (5/7)

In vitro studies were performed comparing ciprofloxacin (Bay o 9867) and norfloxacin with three related organic acids. Ciprofloxacin was two to eight times more active than norfloxacin against 658 bacterial isolates representing 30 species. For all species tested, ciprofloxacin MICs for 90% inhibition were less than or equal to 2.0 micrograms ml. Additional tests with 5,994 isolates detected only 37 (0.6%) strains resistant to 2.0 micrograms of ciprofloxacin per ml and 106 (1.8%) resistant to 1.0 micrograms/ml. Only 6 (0.1%) of the 5,994 strains were resistant to 16 micrograms of norfloxacin per ml, and 129 (2.1%) were resistant to 4.0 micrograms/ml. The majority of resistant strains were streptococci or Pseudomonas spp. Resistance among the Enterobacteriaceae was extremely rare (i.e., greater than 99.8% susceptible to both drugs.  (+info)

Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. (6/7)

Six different gram-negative bacilli were serially transferred through subinhibitory concentrations of seven quinolone derivatives or related organic acids. A gradual, stepwise decrease in susceptibility was noted with all seven drugs, and the resistant cultures demonstrated a concomitant cross-resistance to the other drugs.  (+info)

Influence of urinary pH on the pharmacokinetics of cinoxacin in humans and on antibacterial activity in vitro. (7/7)

The impact of acidification and alkalinization of the urine on the pharmacokinetics of cinoxacin was examined after single 500-mg oral doses were administered to nine healthy male volunteers. Acidic and alkaline conditions were achieved by repeated oral doses of ammonium chloride or sodium bicarbonate, respectively. Plasma cinoxacin levels in all subjects were adequately described in terms of one-compartment-model kinetics with first-order absorption and elimination. Acidification and alkalinization treatment had no effect on cinoxacin absorption or distribution. The mean elimination half-life of cinoxacin in plasma was 1.1, 2.0, and 0.6 h in control subjects and with acidification and alkalinization of urine, respectively. Recovery of intact cinoxacin in samples of urine collected 0 to 36 h after cinoxacin administration represented 65% of the dose in control subjects and urine acidification and 80% of the dose with alkalinization of urine. The mean renal clearance of cinoxacin was 76, 118, and 278 ml/min with acidification, control, and alkalinization, respectively, and renal clearance was highly correlated with urinary pH. Urine concentrations of cinoxacin were significantly higher with alkalinization compared with control values during the first 4 h after drug administration. Urine cinoxacin concentrations were reduced somewhat by acidification, but these tended not to be significantly different from control values. Changes in cinoxacin elimination owing to urine pH are less pronounced in humans than in dogs. The antibacterial activity of cinoxacin against some common urinary tract pathogens was pH dependent. A four- to eightfold reduction in cinoxacin activity was generally observed at pH 8 compared with lower pH values. However, in view of the high levels of cinoxacin which are obtained in both acidic and basic urine, the impact of urine pH on cinoxacin antibacterial efficacy would be of minor clinical importance.  (+info)

Cinoxacin is an antibiotic medication that is used to treat bacterial infections. It is a fluoroquinolone antibiotic, which means that it works by inhibiting the growth of bacteria. Cinoxacin is typically used to treat urinary tract infections, respiratory tract infections, and skin infections. It is usually taken by mouth, although it can also be given intravenously in some cases. Cinoxacin is not effective against all types of bacteria, and it may not work for everyone. It is important to follow your healthcare provider's instructions carefully when taking cinoxacin, and to let them know if you experience any side effects.

Dioxolanes are a class of cyclic ethers that contain two oxygen atoms and one carbon atom in their ring structure. They are commonly used as solvents in various chemical reactions and as intermediates in the synthesis of other compounds. In the medical field, dioxolanes have been studied for their potential use as antiviral agents, particularly against HIV. Some dioxolanes have also been shown to have anti-inflammatory and analgesic properties, and are being investigated as potential treatments for various conditions such as pain and inflammation. However, more research is needed to fully understand the potential therapeutic applications of dioxolanes in medicine.

Pyridazines are a class of heterocyclic compounds that contain a six-membered ring with five carbon atoms and one nitrogen atom. They are commonly used in the medical field as pharmaceuticals and as intermediates in the synthesis of other drugs. Some examples of pyridazine derivatives used in medicine include: 1. Pyridoxine (vitamin B6): A water-soluble vitamin that plays a crucial role in the metabolism of amino acids, lipids, and carbohydrates. 2. Pyridostigmine: A cholinesterase inhibitor used to treat myasthenia gravis, a neuromuscular disorder. 3. Pyrimethamine: An antimalarial drug that inhibits the growth of Plasmodium parasites. 4. Pyrazinamide: An antitubercular drug used to treat tuberculosis. 5. Pyrazinamide: A diuretic used to treat hypertension and edema. Pyridazines have a wide range of pharmacological activities and are used in the treatment of various diseases, including infections, neurological disorders, and metabolic disorders.

Nalidixic acid is an antibiotic medication used to treat bacterial infections, particularly those caused by strains of bacteria that are resistant to other antibiotics. It works by inhibiting the enzyme DNA gyrase, which is essential for bacterial DNA replication. This leads to the death of the bacteria. Nalidixic acid is typically used to treat urinary tract infections, respiratory tract infections, and ear infections caused by susceptible bacteria. It is also sometimes used in combination with other antibiotics to treat more severe infections. However, it is important to note that nalidixic acid is not effective against all types of bacteria and can cause side effects such as nausea, vomiting, and diarrhea. It is also important to complete the full course of treatment as prescribed by a healthcare provider to ensure that the infection is fully treated and to prevent the development of antibiotic resistance.

'Anti-Infective Agents, Urinary' refers to medications that are used to treat urinary tract infections (UTIs) caused by bacteria, viruses, or fungi. These agents are designed to target and eliminate the microorganisms that cause UTIs, thereby reducing inflammation, pain, and other symptoms associated with the infection. Examples of anti-infective agents used to treat UTIs include antibiotics such as trimethoprim-sulfamethoxazole, nitrofurantoin, and cephalosporins. Antiviral agents such as acyclovir may also be used to treat UTIs caused by viruses. In some cases, antifungal agents may be used to treat UTIs caused by fungi. It is important to note that the specific anti-infective agent used to treat a UTI will depend on the type of microorganism causing the infection, as well as the patient's medical history and other factors. It is always important to follow the instructions of a healthcare provider when taking any medication.

Oxolinic acid is a synthetic antibiotic that is used to treat a variety of bacterial infections, including respiratory tract infections, urinary tract infections, and skin infections. It works by inhibiting the growth of bacteria by interfering with their ability to synthesize proteins. Oxolinic acid is available in oral and topical forms and is generally well-tolerated by patients. However, like all antibiotics, it can cause side effects such as nausea, vomiting, and diarrhea. It is important to take oxolinic acid exactly as prescribed by a healthcare provider and to complete the full course of treatment, even if symptoms improve before the medication is finished.

Dioxoles are a class of organic compounds that contain a six-membered ring with two oxygen atoms and two double bonds. They are also known as furan derivatives. In the medical field, dioxoles have been studied for their potential therapeutic properties, including anti-inflammatory, anti-cancer, and anti-viral effects. Some dioxoles have also been used as analgesics and anti-emetics. However, it is important to note that dioxoles can also be toxic and have been associated with adverse effects, such as liver damage and developmental toxicity. Therefore, their use in medicine is carefully regulated and monitored.

Norfloxacin is an antibiotic medication that is used to treat a variety of bacterial infections, including urinary tract infections, respiratory tract infections, skin infections, and gastrointestinal infections. It is a fluoroquinolone antibiotic, which means that it works by inhibiting the growth of bacteria by interfering with their ability to replicate. Norfloxacin is available in both oral and intravenous forms, and it is typically taken for a duration of 7 to 14 days, depending on the type and severity of the infection. It is important to note that norfloxacin should only be used to treat bacterial infections and should not be used to treat viral infections, such as the flu or a cold. Additionally, norfloxacin may interact with other medications, so it is important to inform your healthcare provider of all medications you are currently taking before starting norfloxacin.

Probenecid is a medication that is used to treat gout and to prevent the formation of kidney stones. It works by blocking the reabsorption of uric acid in the kidneys, which helps to lower the levels of uric acid in the blood. Probenecid is usually taken in combination with allopurinol, another medication that helps to lower uric acid levels. It is available in tablet form and is usually taken two to three times a day. Common side effects of probenecid include nausea, vomiting, and stomach pain. It is important to follow the dosage instructions provided by your healthcare provider and to let them know if you experience any side effects while taking this medication.

... was patented in 1972 and assigned to Eli Lilly. Eli Lilly obtained approval from the FDA to market cinoxacin in the ... The marketing authorization of cinoxacin has been suspended throughout the EU. Cinoxacin was an older synthetic antimicrobial ... the older gyrase-inhibitors such as cinoxacin are no longer indicated. Cinoxacin is one of the original quinolone drugs, which ... has also been reported in association with cinoxacin. Animal studies have shown that Cinoxacin is associated with renal damage ...
The first generation also included other quinolone drugs, such as pipemidic acid, oxolinic acid, and cinoxacin, which were ... include cinoxacin, nalidixic acid, and piromidic acid, pipemidic acid The second-generation class is sometimes subdivided into ...
... cinoxacin (INN) cinoxate (INN) cinoxolone (INN) cinoxopazide (INN) cinperene (INN) cinprazole (INN) cinpropazide (INN) ...
J01MB01 Rosoxacin J01MB02 Nalidixic acid J01MB03 Piromidic acid J01MB04 Pipemidic acid J01MB05 Oxolinic acid J01MB06 Cinoxacin ...
Quinolones can be divided into four generations: First generation: nalidixic acid Second generation: cinoxacin, norfloxacin, ...
Be sure to mention anticoagulants (blood thinners) such as warfarin (Coumadin); cimetidine (Tagamet); cinoxacin (Cinobac); ...
... ternary complex with cinoxacin and histamine," Inorganica Chimica Acta, vol. 357, no. 2, pp. 349-353, 2004. ... Oxolinic acid and Cinoxacin. The fluoroquinolones, second generation, like ciprofloxacin are also effective against gram- ...
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in ...
... other quinolone antibiotics such as cinoxacin (Cinobac) (not available in the US), ciprofloxacin (Cipro, Ciloxan), enoxacin ( ...
CINOXACIN 51228 CINOXATE 51229 CIPROFLOXACIN HCL 51230 CISPLATIN 51235 CITRIC ACID 51240 CITRONELLA OIL 51242 CLARITHROMYCIN ...
Cinoxacin Susc Islt 3 LOINC_Long_Common_Name LOINC Long Common Name Cinoxacin [Susceptibility] ...
... cinoxacin(CINX), norfloxacin (NFX), and methacycline (MTC) were the priority antibiotics with mean concentrations > or close to ...
Fluoroquinolone (4-Quinolone) AntibioticsCinoxacin (Cinobac, Pulvules), ciprofloxacin (Ciloxan, Cipro), enoxacin (Penetrex), ...
Cinoxacin D3.494.160 D3.633.300.160 Ciprofloxacin D3.438.810.835.322.186 D3.633.100.810.835.322.186 Circuit-Based Exercise ...
Cinoxacin D3.494.160 D3.633.300.160 Ciprofloxacin D3.438.810.835.322.186 D3.633.100.810.835.322.186 Circuit-Based Exercise ...
Cinoxacin D3.494.160 D3.633.300.160 Ciprofloxacin D3.438.810.835.322.186 D3.633.100.810.835.322.186 Circuit-Based Exercise ...
Cinoxacin D3.494.160 D3.633.300.160 Ciprofloxacin D3.438.810.835.322.186 D3.633.100.810.835.322.186 Circuit-Based Exercise ...
Cinoxacin D3.494.160 D3.633.300.160 Ciprofloxacin D3.438.810.835.322.186 D3.633.100.810.835.322.186 Circuit-Based Exercise ...
Descritores em Ciências da Saúde
Cinoxacin [D03.066.160] * Indoleacetic Acids [D03.066.288] * Isonicotinic Acids [D03.066.349] * Isonipecotic Acids [D03.066.399 ...
CINOXACIN. CINRYZE. CIP - FENOFIBRATE. CIPRO. CIPRO HC. CIPRO HC OTIC. CIPRO I.V.. CIPRO I.V. PHARMACY BULK PACKAGE. CIPRO IV. ...
J01MB06: cinoxacino - cinoxacin *J01MB07: flumequina - flumequine *J01R: COMBINACIONES DE ANTIBACTERIANOS - COMBINATIONS OF ...
... cinoxacin, nalidixic acid, norfloxacin, imipenem (N-formimidoyl-thienamycin), mecillinam and rifampicin was studied by agar and ... In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid. Vuye A. Vuye A. Arzneimittelforschung. ... The susceptibility of Bordetella pertussis to doxycycline, cinoxacin, nalidixic acid, norfloxacin, imipenem (N-formimidoyl- ... Susceptibility of Bordetella pertussis to doxycycline, cinoxacin, nalidixic acid, norfloxacin, imipenem, mecillinam and ...
... and the quinolone antibiotics cinoxacin, nalidixic acid, and pipemidic acid. ...
Cross-resistance between nalidixic acid and other quinolone derivatives such as oxolinic acid and cinoxacin has been observed. ...
Cinoxacin,N0000007043, Sulindac,N0000007042, Oils,N0000007495, Methylmethacrylates,N0000007494, trilostane,N0000007493, ...
Figure 1. Locomotion assay to identify drugs that rescue the scn1Lab mutant epilepsy phenotype. a, Schematic of the phenotype-based screening process. Chemical libraries can be coded and aliquoted in small volumes (75 µL) into individual wells containing one mutant fish. The 96-well microplate is arranged so that six fish are tested per drug; with one row of six fish maintained as an internal control (red circles) on each plate. b, Representative images for WT and scn1Lab mutant zebrafish larvae at 5 dpf. Note the morphological similarity but darker pigmentation in mutant larvae. c, Box plot of mean velocity (in millimeters per second) for two consecutive recordings of mutant larvae in embryo media. Experiments were performed by first placing the mutant larvae in embryo media and obtaining a baseline locomotion response; embryo media was then replaced with new embryo media (to mimic the procedure used for test compounds), and a second locomotion response was obtained. The percentage change in ...
Expert review of hepatotoxicity published in 1999; mentions that cinoxacin, nalidixic acid, ciprofloxacin, norfloxacin, ...
Product containing cinoxacin (medicinal product). Code System Preferred Concept Name. Product containing cinoxacin (medicinal ... Product containing cinoxacin (medicinal product) {96081007 , SNOMED-CT } Parent/Child (Relationship Type) Product containing ... cinoxacin in oral dose form (medicinal product form) {768087002 , SNOMED-CT } Product containing only cinoxacin (medicinal ...
Cinoxacin D3.494.160 D3.633.300.160 Ciprofloxacin D3.438.810.835.322.186 D3.633.100.810.835.322.186 Circuit-Based Exercise ...
Cinoxacin Preferred Term Term UI T008500. Date01/01/1999. LexicalTag NON. ThesaurusID ... Cinoxacin Preferred Concept UI. M0004495. Registry Number. LMK22VUH23. Related Numbers. 28657-80-9. Scope Note. Synthetic ... Cinoxacin. Tree Number(s). D03.066.160. D03.633.300.160. Unique ID. D002937. RDF Unique Identifier. http://id.nlm.nih.gov/mesh/ ...
Cinoxacin Preferred Term Term UI T008500. Date01/01/1999. LexicalTag NON. ThesaurusID ... Cinoxacin Preferred Concept UI. M0004495. Registry Number. LMK22VUH23. Related Numbers. 28657-80-9. Scope Note. Synthetic ... Cinoxacin. Tree Number(s). D03.066.160. D03.633.300.160. Unique ID. D002937. RDF Unique Identifier. http://id.nlm.nih.gov/mesh/ ...
... cinoxacin, E0300987,Circupon,etilefrin, E0300988,Effortil,etilefrine hydrochloride, E0300990,Cisordinol,clopenthixol cis(Z)- ...
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in ...
lsqb;0064] anti-bacterial agents, such as alatrofloxacin, azithromycin, baclofen, benethamine penicillin, cinoxacin, ...
... cinoxacin(CINX), norfloxacin (NFX), and methacycline (MTC) were the priority antibiotics with mean concentrations > or close to ...
ANTI-INFECTIVE AGENTS CINOXACIN ANTI-INFECTIVE AGENTS CIPROFLOXACIN ANTI-INFECTIVE AGENTS CITRININ ANTI-INFECTIVE AGENTS ... URINARY CINOXACIN ANTI-INFECTIVE AGENTS, URINARY CIPROFLOXACIN ANTI-INFECTIVE AGENTS, URINARY CYCLOSERINE ANTI-INFECTIVE AGENTS ... QUINOLONE CINOXACIN ANTI-INFECTIVE AGENTS, QUINOLONE CIPROFLOXACIN ANTI-INFECTIVE AGENTS, QUINOLONE ENOXACIN ANTI-INFECTIVE ...
Cinoxacin D3.494.160 D3.633.300.160 Ciprofloxacin D3.438.810.835.322.186 D3.633.100.810.835.322.186 Circuit-Based Exercise ...
Munekazu G, Takashi K, Yohkazu M, Takako I, Kenji M and Masuhisa N (1983) Effect of cinoxacin on cellular metabolism and p- ...
Descritores em Ciências da Saúde
Cinoxacin, CIN-100. 1. Add to Quote * Ampicillin, AM-10. 1. Add to Quote ...
  • Eli Lilly obtained approval from the FDA to market cinoxacin in the United States as Cinobac on June 13, 1980. (wikipedia.org)
  • Within the most recent package insert (c. 1999) Cinobac is listed as being contraindicated in patients with a history of hypersensitivity to cinoxacin or other quinolones. (wikipedia.org)
  • Cinoxacin was an older synthetic antimicrobial related to the quinolone class of antibiotics with activity similar to oxolinic acid and nalidixic acid. (wikipedia.org)
  • Cinoxacin is similar chemically (and in antimicrobial activity) to oxolinic acid and nalidixic acid. (wikipedia.org)
  • Relative to nalidixic acid, cinoxacin was found to have a slightly greater inhibitory and bactericidal activity. (wikipedia.org)
  • A review of the literature indicates that patients treated with cinoxacin reported fewer adverse drug reactions than those treated with nalidixic acid, furadantin, amoxicillin, or trimethoprim-sulfamethoxazole. (wikipedia.org)
  • examples of these drugs are Nalidixic acid, Oxolinic acid and Cinoxacin. (hindawi.com)
  • Cinoxacin is a quinolone antibiotic that has been discontinued in the U.K. as well the United States, both as a branded drug or a generic. (wikipedia.org)
  • Cinoxacin is one of the original quinolone drugs, which were introduced in the 1970s. (wikipedia.org)
  • Hypersensitivity resulting in an anaphylactic reactions (as seen with all drugs found within this class) has also been reported in association with cinoxacin. (wikipedia.org)